Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096930 | 0.81 | LMNA (0.53) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL6944134 | 0.81 | ALDH1A1 (0.62) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL20665112 | 0.80 | LMNA (0.61) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL7013605 | 0.80 | LMNA (0.56) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL8364740 | 0.80 | LMNA (0.64) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL24943126 | 0.80 | LMNA (0.64) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL7133651 | 0.80 | LMNA (0.58) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL8365517 | 0.77 | LMNA (0.68) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL19002222 | 0.74 | LMNA (0.68) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL6488431 | 0.72 | SMN1; SMN2 (0.61) | LMNASMN1; SMN2POLBALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235798-A4 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | disclosed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1235798-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001032615-A1 | 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | GRIN1, GRIN2A, GRIN2B | LMNA 4661/4885SMN1; SMN2 761/4885POLB 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.